About
Tumor Genome Analysis
Areas of Focus
Categories
Non-PharmaceuticalVirginia, DC, DE & Maryland
Clinical Trials (5)
View allTotal Trials
5
As Lead Sponsor
1
As Collaborator
4
Total Enrollment
5,504
By Phase
PHASE2/PHASE3: 1NA: 2PHASE2: 1
By Status
RECRUITING: 3TERMINATED: 1SUSPENDED: 1
Clinical Trials Pipeline5 trials
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Phase 1/2
Phase 2/3
N/A
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
2031
2032
2033
2034
2035
2036
Today
Hover over trial bars to see details
Recent Trials
NCT05585684Collaborator
Liquid Biopsy-informed Precision Oncology Study to Evaluate Utility of Plasma Genomic Profiling for Therapy Selection
N/ARecruiting
150 participants
Started: Jan 27, 2023 · Completed: Sep 30, 2027
NCT04093167Collaborator
Study of CTDNA Response Adaptive Immuno-Chemotherapy in NSCLC
PHASE2/PHASE3Recruiting
230 participants
Started: May 26, 2020 · Completed: Jul 30, 2027
NCT06434896Collaborator
Circulating Tumor DNA Based Adjuvant Chemotherapy in Stage II Colon Cancer Patients: the MEDOCC-CrEATE Trial
NARecruiting
1,320 participants
Started: Mar 5, 2020 · Completed: Mar 31, 2035
NCT03461952Collaborator
Nivolumab Ipilimumab in Patients With hyperMutated Cancers Detected in Blood (NIMBLe)
PHASE2Terminated
4 participants
Started: Mar 11, 2019 · Completed: Feb 9, 2022
NCT01305148Lead Sponsor
Warfarin Adverse Event Reduction For Adults Receiving Genetic Testing at Therapy INitiation (WARFARIN)
NASuspended
3,800 participants
Started: Aug 31, 2011 · Completed: Dec 31, 2015
Locations (1)
Headquarters
Baltimore, MD, United States
Map
Loading map...